Design and rationale of the CLEAR SYNERGY (OASIS 9) trial: A 2x2 factorial randomized controlled trial of colchicine versus placebo and spironolactone vs placebo in patients with myocardial infarction
Marc-André d’Entremont(Centre Hospitalier Universitaire de Sherbrooke), Sanjit S. Jolly(Population Health Research Institute), Timothy D. Henry(Christ Hospital), Rajibul Mian(Population Health Research Institute), Jan H. Cornel(Brigham and Women's Hospital), Gilles Montalescot(Maastricht University Medical Centre), Jessica Tyrwhitt(Population Health Research Institute), Shun Fu Lee(Population Health Research Institute), Robert F. Storey(University of Sheffield), P.J. Devereaux(University of Limerick), Goran Stanković(University of Belgrade), Elizabeth Skuriat(Population Health Research Institute), Shamir R. Mehta(Population Health Research Institute), Sasko Kedev(Ss. Cyril and Methodius University in Skopje), John W. Eikelboom(Population Health Research Institute), Bertram Pitt(University of Michigan), Raúl Moreno(Hospital Universitario La Paz), John A. Cairns
Cited by 31
Related Papers
Dabigatran versus Warfarin in Patients with Atrial Fibrillation
|New England Journal of Medicine|2009|11.2k
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
|New England Journal of Medicine|2017|9.1k
Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
|New England Journal of Medicine|2009|7.1k
Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes
|New England Journal of Medicine|2007|6.7k